Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (855)	7/7/2005 2:07:04 PM
From: nigel bates	Respond to of 1127

(Comment from Forbes, FWIW...) ....Thursday morning, Human Genome Sciences (nasdaq: HGSI) announced that drug giant GlaxoSmithKline (nyse:GSK ) had decided to exercise its option to co-develop and co-promote the biotech's LymphoStat-B experimental treatment for rheumatoid arthritis and lupus. Analysts at CIBC World Markets wrote in a note to investors this morning that the deal validates the drug's potential. Glaxo and HGS will now equally split clinical trial costs, marketing expenses, and profits. The deal, the analysts wrote, will give Human Genome the deep pockets needed to compete with Biogen Idec (nasdaq: BIIB ) and Genentech (nyse: DNA), whose Rituxan may enter trials for lupus soon. Phase II results for LymphoStat-B that could lead to approval, if positive, are expected in the fourth quarter and are characterized by CIBC as "extremely important." --Matthew Herper